Gelonghui March 12 | Xima Ophthalmology (03309.HK) announced that according to the currently available unaudited financial data for the year ended 31 December 2023, the company is expected to turn a loss into a profit, bringing the profit attributable to the company's equity holders to HK$60 million to HK$65 million, while a loss attributable to equity holders was recorded at HK$21.9 million for the year ended 31 December 2022.
The expected increase in profit attributable to the company's equity holders is mainly driven by revenue from medical services, which increased by more than 30% from HK$1.43 billion in FY2022 to around HK$1.9 billion in FY2023, but partially offset by a reduction in revenue from the sale of COVID-19-related medical consumables from HK$298 million in FY2022 to around HK$19 million in FY2023.
The Group continues to notice continued demand from China and Hong Kong for the Group's ophthalmology and dental services business. Coupled with the re-clearance of customs between Hong Kong and Shenzhen, the Group's dental business in Shenzhen under the “Shenzhen iHealth” brand recorded a significant increase in revenue and turned into a profit in the 2023 fiscal year.